Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 2, 2015, Pages

  Coppola, Antonio ^a   Windyga, Jerzy ^b   Tufano, Antonella ^a   Yeung, Cindy ^c   Di Minno, Matteo Nicola Dario ^a,d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^c MCMASTER UNIVERSITY   (Canada)

^d CENTRO CARDIOLOGICO MONZINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; HEMOSTATIC AGENT; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

AGING; BLEEDING DISORDER; BLOOD TRANSFUSION; BOLUS INJECTION; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; META ANALYSIS; MINOR SURGERY; MORTALITY; OPERATIVE BLOOD LOSS; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TOOTH EXTRACTION; TREATMENT DURATION; TREATMENT OUTCOME; WOUND HEALING; BLOOD LOSS, SURGICAL; HEMOSTASIS; PROCEDURES; SURGERY;

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENTS; BLOOD LOSS, SURGICAL; FACTOR VIIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS, SURGICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; SURGICAL PROCEDURES, OPERATIVE; TOOTH EXTRACTION; TRANEXAMIC ACID;

EID: 84934343015     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009961.pub2     Document Type: Review

References (68)

1. Forbes CD, Barr RD, Reid G, Thomson C, Prentice CRM, McNicol GP, et al. Tranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease. British Medical Journal 1972;2:311-3.
2. Pruthi RK, Mathew P, Valentino LA, Sumner MJ, Seremetis S, Hoots WK, et al. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thrombosis and Haemostasis 2007;98:726-32.
3. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thrombosis and Haemostasis 1998;80(5):773-8.
4. Walsh PN, Rizza CR, Matthews JM, Eipe J, Kernoff PBA, Coles MD, et al. Epsilon-aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial. British Journal of Haematology 1971;20:463-75.
5. Avanoglu A, Celik A, Ulman I, Ozcan C, Kavakli K, Nisli G, et al. Safer circumcision in patients with haemophilia: the use of fibrin glue for local haemostasis. BJU International 1999;83:91-4.
6. Batorova A, Martinowitz U. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. British Journal of Haematology 2000;110:715-20.
7. Jiménez-Yuste V, Prim MP, De Diego JI, Villar A, Quintana M, Rabanal I. Otolaryngologic surgery in children with von Willebrand Disease. Archives of Otolaryngologologic Head Neck Surgery 2002;128:1365-8.
8. Rakocz M, Mazar A, Varon D, Spierer S, Blinder D, Martinowitz U. Dental extractions in patients with bleeding disorders. The use of fibrin glue. Oral Surgery Oral Medicine Oral Pathology 1993;75:280-2.
9. Ramstrom G, Blomback M. Tooth extractions in haemophiliacs. International Journal Oral Surgery 1975;4:1-17.
10. Sindet-Pedersen S, Stenbjerg S. Effect of local antifibrinolytic treatment with tranexamic acid in hemophiliacs undergoing oral surgery. Journal Oral Maxillofacial Surgery 1986;44:703-7.
11. Stajcic Z. The combined local/systemic use of antifibrinolytics in hemophiliacs undergoing dental extractions. International Journal Oral Surgery 1985;14:339-45.
12. Stajcic Z, Baklaja R, Elezovic I, Rolovic Z. Primary wound closure in haemophiliacs undergoing dental extractions. International Journal of Oral and Maxillofacial Surgery 1989;18:14-6.
13. Tavenner RW. Use of tranexamic acid in control of haemorrhage after extraction of teeth in haemophilia and Christmas disease. British Medical Journal 1972;2:314-5.
14. Waly NG. Local antifibrinolytic treatment with tranexamic acid in hemophilic children undergoing dental extractions. Egyptian Dental Journal 1995;41:961-8.
15. Lee AP, Boyle CA, Savidge GF, Fiske J. Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash. British Dental Journal 2005;198(1):33-8.
16. NCT00357656 . Phase 3/4 study of a recombinant protein-free factor VIII (rAHF-PFM): comparison of continuous infusion versus intermittent bolus infusion in hemophilia A subjects undergoing major orthopedic surgery. http://clinicaltrials.gov/show/NCT00357656 (accessed 17 March 2014).
17. Aledort LM, Haschmeyer RH, Pettersson H, the Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. Journal of Internal Medicine 1994;236(4):391-9.
18. Aoki N. Hemostasis associated with abnormalities of fibrinolysis. Blood Reviews 1989;3(1):11-7.
19. Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia 2010;16(102):66-70.
20. Becker MP, Balagtas CC. Marginal modeling of binary cross-over data. Biometrics 1993;49(4):997-1009.
21. Berntorp E. Guidelines on treatment of haemophilia in Sweden. Haemophilia 1998;4(4):425-6.
22. Bolton-Maggs PHB, Chalmers EA, Collins PW, Harrison P, Kitchen S, Liesner RJ, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. British Journal of Haematology 2006;135(5):603-33.
23. Brooker M. Registry of clotting factor concentrates. 9th Edition, 2012. Facts and Figures, available at http://www1.wfh.org/publication/files/pdf-1227.pdf 2012, issue 6.
24. Collins PW, Chalmers E, Hart DP, Liesner R, Rangarajan S, Talks K, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors. British Journal of Haematology 2013;160(2):153-70.
25. Coppola A, Di Minno G. Desmopressin in the treatment of platelet function abnormalities. Haemophilia 2008;14(Suppl 1):31-9.
26. Coppola A, Santoro C, Franchini M, Mannucci C, Mogavero S, Molinari AC, et al. Emerging issues on comprehensive hemophilia care: preventing, identifying and monitoring age-related comorbidities. Seminars in Thrombosis and Hemostasis 2013;39(7):794-802.
27. Cosmi B, Alatri A, Cattaneo M, Gresele P, Marietta M, Rodeghiero F, et al. Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research 2009;124(5):e6-e12.
28. Deeks J, Higgins J, Altman D. Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
29. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. British Journal of Haematology 2007;138(3):305-15.
30. Donner A, Piaggio G, Villar J. Statistical methods for the meta-analysis of cluster randomized trials. Statistical Methods in Medical Research 2001;10(5):325-38.
31. Eckhardt CL, van der Bom JG, van der Naald M, Peters M, Kamphuisen PW, Fijnvandraat K. Surgery and inhibitor development in hemophilia A: a systematic review. Journal of Thrombosis and Haemostasis 2011;9(10):1948-58.
32. Eckhardt CL, Mauser-Bunschoten EP, Peters M, Leebeek FW, van der Meer FJ, Fijnvandraat K. Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands. British Journal of Haematology 2012;157(6):747-52.
33. Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013;122(11):1954-62.
34. Federici AB. Diagnosis of inherited von Willebrand disease: a clinical perspective. Seminars in Thrombosis and Hemostasis 2006;32(6):555-65.
35. Franchini M, Manzato F, Salvagno GL, Montagnana M, Lippi G. The use of desmopressin in congenital factor XI deficiency: a systematic review. Annals of Hematology 2009;88(10):931-35.
36. Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet Journal of Rare Diseases 2012;7:24.
37. Giangrande PLF, Wilde JT, Madan B, Ludlam CA, Tuddenham EGD, Goddard NJ, et al. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven®] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia 2009;15(2):501-8.
38. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM, American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e227S-77S.
39. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007;109(11):4648-54.
40. Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013;121(20):4046-55.
41. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003;102(7):2358-63.
42. Hermans C, Altisent C, Batorova A, Chambost H, De Moerloose P, Karafoulidou A, et al. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia 2009;15(3):639-58.
43. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
44. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011:available from www.cochrane-handbook.org.
45. James PD, Lillicrap D, Mannucci PM. Alloantibodies in von Willebrand disease. Blood 2013;122(5):636-40.
46. Karanth L, Barua A, Kanagasabai S, Nair NS. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD009824]
47. Mannucci PM. Hemostatic drugs. New England Journal of Medicine 1998;339(4):245-53.
48. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. New England Journal of Medicine 2001;344(23):1773-9.
49. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004;104(5):1243-52.
50. Mannucci PM, Franchini M, Castaman G, Federici AB, on behalf of AICE (Italian Association of Hemophilia Centres) other authors are listed at the end of the manuscript. Evidence-based treatment of von Willebrand disease in Italy. Blood Transfusion 2009;7(2):117-26.
51. Mannucci PM, Schutgens RE, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with hemophilia. Blood 2009;114(26):5256-63.
52. Martinowitz U, Schulman S, Gitel S, Horoszowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. British Journal of Haematology 1992;82(4):729-34.
53. Martinowitz U, Schulman S. Coagulation factors concentrations by continuous infusion. Transfusion Medicine Reviews 1997;11(1):56-63.
54. Mauser-Bunschoten EP, Roosendaal G, Van Den Berg HM. Product choice and haemophilia treatment in the Netherlands. Haemophilia 2001;7(1):96-8.
55. Nurden AT. Qualitative disorders of platelets and megakariocytes. Journal of Thrombosis and Haemostasis 2005;3(8):1773-82.
56. Pavlova A, Oldenburg J. Defining severity of haemophilia: More than factor levels. Seminars in Thrombosis and Hemostasis 2013;39(7):702-10.
57. Peyvandi F, Di Michele D, Bolton-Maggs PHB, Lee CA, Tripodi A, Srivastava A. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. Journal of Thrombosis and Haemostasis 2012;10(9):1938-43.
58. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987;69(2):454-9.
59. Santagostino E, Mannucci PM, for the Italian Association of Haemophilia Centres (AICE). Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 2000;6(1):1-10.
60. Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006;12(2):154-62.
61. Sharathkumar A, Lillicrap D, Blanchette VS, Kern M, Leggo J, Stain AM, et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. Journal of Thrombosis and Haemostasis 2003;1(6):1228-36.
62. Srivastava A, Brewer AK, Mauser-Bunschoten P, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia 2013;19:e1-e47.
63. Stonebraker JS, Brooker M, Amand RE, Farrugia A, Srivastava A. A study of reported FVIII use around the world. Haemophilia 2010;16(1):33-46.
64. Teitel JM. National haemophilia treatment protocols: Canada. Haemophilia 1998;4(4):422-3.
65. United Kingdom Haemophilia Centre Doctors' Organisation. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003;9(3):1-23.
66. White II GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thrombosis and Haemostasis 2001;85(3):560.
67. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A. A systematic review. Haemophilia 2003;9(4):418-35.
68. Xi M, Makris M, Marcucci M, Santagostino E, Mannucci PM, Iorio A. Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. Journal of Thrombosis & Haemostasis 2013;11(9):1655-62.